Pharmacy, Health Sciences & Exercise Science

Event Title

A Comparison of the Safety and Efficacy of P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: A Retrospective Chart Review

Document Type

Oral Presentation

Location

Indianapolis, IN

Subject Area

Pharmacy, Health Sciences & Exercise Science

Start Date

11-4-2014 8:30 AM

End Date

11-4-2014 10:00 AM

Description

Background:Each year it is estimated that 635,000 Americans have a primary coronary event, defined as a first hospitalized myocardial infarction (MI) or coronary heart disease death. These acute coronary syndromes (ACS) result from coronary artery occlusion in the presence of a thrombus. This oftentimes requires mediation with percutaneous coronary intervention (PCI) that in turn requires dual antiplatelet therapy with aspirin and a P2Y12 for up to 12 months to prevent platelet aggregation and future coronary events. The drugs vary in their pros and cons which can lead to a variety of choices when prescribing for these particular patients.

Study Objective: The goal of the study is to determine all cause 30 day re-admission rates between clopidogrel, prasugrel, and ticagrelor. Secondarily, it was determined to look at rates of readmission due to cardiac causes, recurrent MI/PCI rates, hospital length of stay, and compliance to medication.

Methods: The study is in the process of collecting data through a retrospective chart review investigating the prescribing patterns of P2Y12 inhibitors for dual antiplatelet therapy in patients undergoing PCI at IU Health network.

Descriptive statistics will be used to report the incidence of each individual endpoint for each of the antiplatelet drugs studied. Statistical significance, if it exists, will be evaluated based on percent incidence of these respective endpoints.

Significance: Data from this project will be used to attempt to determine whether current prescribing patterns of P2Y12 inhibitors are optimal.

This document is currently not available here.

Share

COinS
 
Apr 11th, 8:30 AM Apr 11th, 10:00 AM

A Comparison of the Safety and Efficacy of P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: A Retrospective Chart Review

Indianapolis, IN

Background:Each year it is estimated that 635,000 Americans have a primary coronary event, defined as a first hospitalized myocardial infarction (MI) or coronary heart disease death. These acute coronary syndromes (ACS) result from coronary artery occlusion in the presence of a thrombus. This oftentimes requires mediation with percutaneous coronary intervention (PCI) that in turn requires dual antiplatelet therapy with aspirin and a P2Y12 for up to 12 months to prevent platelet aggregation and future coronary events. The drugs vary in their pros and cons which can lead to a variety of choices when prescribing for these particular patients.

Study Objective: The goal of the study is to determine all cause 30 day re-admission rates between clopidogrel, prasugrel, and ticagrelor. Secondarily, it was determined to look at rates of readmission due to cardiac causes, recurrent MI/PCI rates, hospital length of stay, and compliance to medication.

Methods: The study is in the process of collecting data through a retrospective chart review investigating the prescribing patterns of P2Y12 inhibitors for dual antiplatelet therapy in patients undergoing PCI at IU Health network.

Descriptive statistics will be used to report the incidence of each individual endpoint for each of the antiplatelet drugs studied. Statistical significance, if it exists, will be evaluated based on percent incidence of these respective endpoints.

Significance: Data from this project will be used to attempt to determine whether current prescribing patterns of P2Y12 inhibitors are optimal.